UK +44 (0)1223 491486      USA toll free 1-866 877 2185

Search
Generic filters
8 03, 2021

Catherine Elton, Qkine founder and CEO, recognised in the #21towatch in 2021

By |2022-02-07T13:31:52+00:00March 8th, 2021|awards, news|Comments Off on Catherine Elton, Qkine founder and CEO, recognised in the #21towatch in 2021

The #21toWatch campaign showcases 7 people, 7 companies and 7 inventions at the forefront of innovation in Cambridge and the East of England. The results were announced on the 4th March and we are delighted that our CEO, Catherine Elton, was named one of the 7 “people” to watch.

25 11, 2020

Qkine, with UK biotechnology companies Manchester BIOGEL and Cellesce, is developing fully synthetic animal-free scaffolds to overcome barriers in sustainable and scalable organoid culture, in a project funded by Innovate UK

By |2022-02-07T13:30:35+00:00November 25th, 2020|animal-free, news, organoid news|Comments Off on Qkine, with UK biotechnology companies Manchester BIOGEL and Cellesce, is developing fully synthetic animal-free scaffolds to overcome barriers in sustainable and scalable organoid culture, in a project funded by Innovate UK

Qkine, Manchester BIOGEL and Cellesce have been awarded Innovate UK Sustainable Innovation Funding to develop fully synthetic, chemically-defined three-dimensional (3D) scaffolds to enable manufacture scale up and improve reproducibility of patient-derived organoids.

11 11, 2020

Qkine shortlisted in the Cambridge Independent 2020 Science & Technology awards

By |2022-02-07T13:29:16+00:00November 11th, 2020|awards, news|Comments Off on Qkine shortlisted in the Cambridge Independent 2020 Science & Technology awards

Qkine shortlisted in the Cambridge Independent 2020 Science & Technology awards Qkine is delighted to have been shortlisted in the prestigious Cambridge Independent 2020 Science and Technology Awards. Sponsored by Kao Data, the Startup of the Year shortlist recognises "early-stage companies that show entrepreneurial drive to solve a problem, or improve [...]

9 11, 2020

Organoid Q&A with industry experts from the HUB, CSHL and Stemnovate

By |2022-02-07T13:18:02+00:00November 9th, 2020|organoid news, quality, resources|Comments Off on Organoid Q&A with industry experts from the HUB, CSHL and Stemnovate

Organoid Q&A with industry experts from the HUB, CSHL and Stemnovate We recently held a webinar with CytoSMART and organoid pioneers from Cold Spring Harbor Laboratory, Stemnovate and the Hubrecht Organoid Technology titled: what's needed to realize the potential of organoids? Following presentations from our speakers, we held an insightful [...]

14 10, 2020

On-demand webinar: What’s needed to realise the potential of organoids?

By |2022-02-07T13:09:14+00:00October 14th, 2020|organoid news, quality, resources|Comments Off on On-demand webinar: What’s needed to realise the potential of organoids?

On-demand webinar: What’s needed to realise the potential of organoids? From standardization of imaging techniques, to more reproducible and cost-effective organoid culture media Organoids have the potential to revolutionize current drug discovery approaches, enhance the physiological relevance of in vitro disease models, and deliver on the promise of precision medicine. But, [...]

26 08, 2020

Implementing animal-free recombinant proteins into stem cell supply chains

By |2022-02-07T13:06:59+00:00August 26th, 2020|animal-free, protein engineering, quality, stem cells|Comments Off on Implementing animal-free recombinant proteins into stem cell supply chains

Implementing animal-free recombinant proteins into stem cell supply chains Most industries today are under pressure to switch to more ethical and sustainable animal-free alternatives, and now the trend is coming to stem cell labs. As stem cell applications accelerate towards the clinic, novel drug discovery platforms are rapidly scaled, and [...]

21 07, 2020

Rob Nixon joins Qkine as Head of Commercial and Dr Cassie Doherty is appointed to the board

By |2020-12-08T16:06:23+00:00July 21st, 2020|news, press release|Comments Off on Rob Nixon joins Qkine as Head of Commercial and Dr Cassie Doherty is appointed to the board

Cambridge, UK 21 July 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – is delighted to announce the appointment of Rob Nixon to its management team as Head of Commercial and Dr Cassie Doherty, Investment Director at Parkwalk, to its board. With years of [...]

15 06, 2020

Video: Growth factor purity and its implications for stem cell culture

By |2020-12-08T15:54:08+00:00June 15th, 2020|protein engineering, protein science, quality, stem cells|Comments Off on Video: Growth factor purity and its implications for stem cell culture

Presentation by Luana Ferrara, Senior Protein Scientist Video script Slide 1: Introduction  Hello! My name is Luana Ferrara and I am a senior protein scientist at Qkine. In this short video, I’ll be presenting a comparative analysis of the purity of recombinant Activin A from different suppliers and highlighting why it's important to consider the biochemical quality of growth factors for your stem cell culture.   Slide 2: The role of [...]

8 06, 2020

Qkine secures £1.5M series A funding from leading life science investors

By |2022-02-07T11:50:51+00:00June 8th, 2020|news, press release|Comments Off on Qkine secures £1.5M series A funding from leading life science investors

Qkine secures £1.5M series A funding from leading life science investors Cambridge, UK 08 June 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – today announced the successful closure of a £1.5M series A investment round to accelerate the global [...]

3 06, 2019

Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio

By |2022-02-07T11:49:25+00:00June 3rd, 2019|news, press release|Comments Off on Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio

Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio Cambridge, UK 03 June 2019: Qkine, specialist manufacturer of proteins for stem cell, organoid and regenerative medicine applications, has closed a further round of investment. The £550K funding round was led by Cambridge Enterprise [...]

Title

Go to Top